Articaine hydrochloride, also referenced in older pharmacopoeial literature as carticaine hydrochloride, is a thiophene-containing amide local anesthetic supplied as a pharmaceutical-grade active pharmaceutical ingredient for injectable dental anesthesia and for selected oromucosal granule, tablet, or capsule intermediates where local contact anesthesia is intended. The current INN is articaine; carticaine is a superseded synonym and does not designate a separate salt, polymorph, or impurity profile. The substance is methyl 4-methyl-3-[2-(propylamino)propanamido]thiophene-2-carboxylate hydrochloride, CAS 23964-58-1, free base CAS 23964-57-0, with relative molecular mass 320.84 g/mol. It is supplied as a white to almost white crystalline powder, freely soluble in water, with a pKa of 7.8 and plasma protein binding of approximately 94%. Unlike lidocaine, the molecule contains a thiophene ring in place of a benzene ring and a methyl ester side chain that is hydrolyzed by plasma esterases to the inactive metabolite articainic acid. This esterase pathway is the principal reason systemic residence time is shorter than that of amide anesthetics metabolized mainly in the liver.

Grade differentiation is not expressed as a device-style model number. The API is defined by specification modules: a compendial assay and related substances panel, a residual solvent profile under ICH Q3C, an elemental impurity profile under ICH Q3D, and an injection-specific module for bacterial endotoxins and subvisible particulate matter. Certificates of analysis issued for pharmaceutical use reference GMP conditions under ICH Q7 and, depending on the intended market, the current European Pharmacopoeia or United States Pharmacopeia monograph. For injectable products, the final formulation is commonly a clear aqueous solution containing 4% articaine hydrochloride with epinephrine 1:100,000 or 1:200,000; a 1.8 mL dental cartridge contains 72 mg articaine hydrochloride, while a 1.7 mL cartridge contains 68 mg. The maximum recommended dose in healthy adults cited in prescribing information is 7 mg/kg, not to exceed 500 mg per appointment.

Why does the same API require divergent particle specifications for sterile injectable and granulated solid forms?

For parenteral use, the powder is dissolved in Water for Injection, so the primary physical concerns shift from dissolution rate to filtration, clarity, and particulate control. Injectable-grade articaine hydrochloride must dissolve to a clear solution, and the final sterilized solution is tested for subvisible particles using USP <788> and for bacterial endotoxins using USP <85>. Dry powder terminal sterilization is uncommon; the formulated solution is aseptic-filtered through a 0.22 µm membrane, and the cartridge is filled in an ISO class 5 environment. For solid oromucosal forms such as granules, capsules, or compressed tablets, particle size distribution becomes a critical content-uniformity variable. Milled API grades are typically controlled by laser diffraction with Ph. Eur. 2.9.31 or USP <429>; a D90 below 150 µm is often used for dry blending, but the exact D10, D50, and D90 limits are agreed between the API supplier and the dosage-form manufacturer because no universal pharmacopoeial D90 value exists. Water content is measured by Karl Fischer titration per Ph. Eur. 2.5.12 or USP <921>. Containers opened at ambient relative humidity above 60% should be reclosed immediately and re-tested if moisture excursion is suspected.

Representative regulatory and chemical specification matrix for compendial articaine hydrochloride:

When articaine hydrochloride replaces lidocaine in mandibular infiltration anesthesia

Substitution is not a simple equipotent switch. The pKa of 7.8 gives a non-ionized free base fraction of approximately 28% at tissue pH 7.4, compared with about 24% for lidocaine at pKa 7.9; the difference contributes to rapid onset but is insufficient alone to explain clinical behavior. Plasma esterase hydrolysis produces articainic acid and a terminal half-life of roughly 20 minutes, which reduces accumulation risk but shortens duration if a vasoconstrictor is omitted. Compared with bupivacaine pKa 8.1 and protein binding 95%, articaine has faster onset and shorter pulpal duration. Compared with prilocaine, articaine does not generate the o-toluidine metabolite associated with methemoglobinemia. Clinical trials of mandibular buccal infiltration in permanent first molars have reported superiority over lidocaine in some randomized comparisons, but the effect size is not uniform across all teeth and patient groups; published data for this specific configuration are limited.

Comparative physicochemical and formulation boundaries for common injectable amide local anesthetics:

Sterile filtration, oxygen exclusion, and epinephrine co-formulation limits

Production of articaine hydrochloride dental cartridges is constrained by the stability of both the API and the co-formulated epinephrine. The ester linkage in articaine is susceptible to acid- and base-catalyzed hydrolysis, so the formulation pH is kept within a narrow acidic window through sodium hydroxide/hydrochloric acid adjustment, and forced-degradation studies are required to demonstrate mass balance. Epinephrine bitartrate is oxygen-sensitive; filling is therefore performed under nitrogen or vacuum, with sodium metabisulfite as antioxidant. Terminal moist-heat sterilization is not the preferred method for epinephrine-containing cartridges because heat destroys epinephrine; aseptic filtration through 0.22 µm polyethersulfone membranes followed by cartridge filling in an ISO class 5 environment is standard. Stainless steel product-contact surfaces are passivated, and the filtration train is flushed to remove extractables before use. Batch records should include filter integrity tests, fill-volume checks, and in-process epinephrine assay because the vasoconstrictor can adsorb to certain filter polymers if the formulation is not optimized.

Although injectable use dominates the clinical monograph, articaine hydrochloride can be incorporated into solid oromucosal matrices if the intended product is a local-contact anesthetic tablet, granule, or capsule. The hydrochloride salt is highly water-soluble and bitter; fluid-bed granulation with an aqueous binder can dissolve the API and redistribute it onto granule surfaces, altering dissolution and content uniformity. Low spray rates and staged binder addition reduce this migration. Direct compression requires a free-flowing coarse filler and may use larger API particle sizes to prevent segregation; roller compaction of a preblend can improve flow but may alter the crystal surface and dissolution. Capsule filling for systemic oral use is not a standard clinical presentation because plasma esterase hydrolysis limits systemic exposure and the bitter API is not suited to immediate-release oral delivery without taste masking. Published data for systemic oral solid dosage forms of articaine hydrochloride are limited; injectable dental cartridges and oromucosal topical preparations remain the principal pharmaceutical presentations.